These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19722264)

  • 1. Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES.
    Jin H; Kagiampakis I; Li P; Liwang PJ
    Proteins; 2010 Feb; 78(2):295-308. PubMed ID: 19722264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor.
    Guan X; Chaffey PK; Chen H; Feng W; Wei X; Yang LM; Ruan Y; Wang X; Li Y; Barosh KB; Tran AH; Zhu J; Liang W; Zheng YT; Wang X; Tan Z
    Biochemistry; 2018 Jan; 57(1):136-148. PubMed ID: 29202246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.
    Hartley O; Dorgham K; Perez-Bercoff D; Cerini F; Heimann A; Gaertner H; Offord RE; Pancino G; Debré P; Gorochov G
    J Virol; 2003 Jun; 77(12):6637-44. PubMed ID: 12767983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly potent chimeric inhibitors targeting two steps of HIV cell entry.
    Zhao B; Mankowski MK; Snyder BA; Ptak RG; Liwang PJ
    J Biol Chem; 2011 Aug; 286(32):28370-81. PubMed ID: 21659523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.
    Secchi M; Longhi R; Vassena L; Sironi F; Grzesiek S; Lusso P; Vangelista L
    Chem Biol; 2012 Dec; 19(12):1579-88. PubMed ID: 23261601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of N-Terminal Cyclization on the Function of the HIV Entry Inhibitor 5P12-RANTES.
    F Nguyen A; S Schill M; Jian M; J LiWang P
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28726743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of novel HIV-1 entry inhibitors by RANTES engineering.
    Vangelista L; Secchi M; Lusso P
    Vaccine; 2008 Jun; 26(24):3008-15. PubMed ID: 18243436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
    Mosier DE; Picchio GR; Gulizia RJ; Sabbe R; Poignard P; Picard L; Offord RE; Thompson DA; Wilken J
    J Virol; 1999 May; 73(5):3544-50. PubMed ID: 10196243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES.
    Wilken J; Hoover D; Thompson DA; Barlow PN; McSparron H; Picard L; Wlodawer A; Lubkowski J; Kent SB
    Chem Biol; 1999 Jan; 6(1):43-51. PubMed ID: 9889151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semisynthetic analogues of PSC-RANTES, a potent anti-HIV protein.
    Gaertner H; Offord R; Botti P; Kuenzi G; Hartley O
    Bioconjug Chem; 2008 Feb; 19(2):480-9. PubMed ID: 18179159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment.
    Melikyan GB; Platt EJ; Kabat D
    Retrovirology; 2007 Aug; 4():55. PubMed ID: 17686153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional analysis of the RANTES-glycosaminoglycans interactions.
    Martin L; Blanpain C; Garnier P; Wittamer V; Parmentier M; Vita C
    Biochemistry; 2001 May; 40(21):6303-18. PubMed ID: 11371192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
    Pastore C; Picchio GR; Galimi F; Fish R; Hartley O; Offord RE; Mosier DE
    Antimicrob Agents Chemother; 2003 Feb; 47(2):509-17. PubMed ID: 12543651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of structure, dynamics, and detergent interactions of the anti-HIV chemokine variant 5P12-RANTES.
    Wiktor M; Hartley O; Grzesiek S
    Biophys J; 2013 Dec; 105(11):2586-97. PubMed ID: 24314089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.
    Blanpain C; Buser R; Power CA; Edgerton M; Buchanan C; Mack M; Simmons G; Clapham PR; Parmentier M; Proudfoot AE
    J Leukoc Biol; 2001 Jun; 69(6):977-85. PubMed ID: 11404385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling.
    Burns JM; Gallo RC; DeVico AL; Lewis GK
    J Exp Med; 1998 Nov; 188(10):1917-27. PubMed ID: 9815269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4.
    Gaertner H; Lebeau O; Borlat I; Cerini F; Dufour B; Kuenzi G; Melotti A; Fish RJ; Offord R; Springael JY; Parmentier M; Hartley O
    Protein Eng Des Sel; 2008 Feb; 21(2):65-72. PubMed ID: 18178567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants.
    Secchi M; Xu Q; Lusso P; Vangelista L
    Protein Expr Purif; 2009 Nov; 68(1):34-41. PubMed ID: 19573605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.